G

Genovis AB
STO:GENO

Watchlist Manager
Genovis AB
STO:GENO
Watchlist
Price: 28.05 SEK 3.13% Market Closed
Market Cap: 1.8B SEK
Have any thoughts about
Genovis AB?
Write Note

Genovis AB
Other Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Genovis AB
Other Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Equity CAGR 3Y CAGR 5Y CAGR 10Y
G
Genovis AB
STO:GENO
Other Equity
kr207.6m
CAGR 3-Years
32%
CAGR 5-Years
48%
CAGR 10-Years
22%
AddLife AB
STO:ALIF B
Other Equity
kr5B
CAGR 3-Years
N/A
CAGR 5-Years
40%
CAGR 10-Years
N/A
BICO Group AB
STO:BICO
Other Equity
kr3.1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biotage AB
STO:BIOT
Other Equity
kr30m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
MedCap AB (publ)
STO:MCAP
Other Equity
kr1.2B
CAGR 3-Years
23%
CAGR 5-Years
30%
CAGR 10-Years
17%
M
Magle Chemoswed Holding AB
STO:MAGLE
Other Equity
kr40.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Genovis AB
Glance View

Market Cap
1.8B SEK
Industry
Life Sciences Tools & Services

Genovis AB engages in the research and development of enzyme products. The company is headquartered in Lund, Skane. The company went IPO on 2005-11-11. The firm offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The firm markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.

GENO Intrinsic Value
24.64 SEK
Overvaluation 12%
Intrinsic Value
Price
G

See Also

What is Genovis AB's Other Equity?
Other Equity
207.6m SEK

Based on the financial report for Jun 30, 2024, Genovis AB's Other Equity amounts to 207.6m SEK.

What is Genovis AB's Other Equity growth rate?
Other Equity CAGR 10Y
22%

Over the last year, the Other Equity growth was 11%. The average annual Other Equity growth rates for Genovis AB have been 32% over the past three years , 48% over the past five years , and 22% over the past ten years .

Back to Top